Janney Montgomery Scott LLC Sells 93,748 Shares of Zoetis Inc. $ZTS

Janney Montgomery Scott LLC lowered its stake in Zoetis Inc. (NYSE:ZTS) by 60.0% during the 2nd quarter, HoldingsChannel reports. The firm owned 62,464 shares of the company’s stock after selling 93,748 shares during the period. Janney Montgomery Scott LLC’s holdings in Zoetis were worth $4,489,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Brighton Jones LLC lifted its holdings in shares of Zoetis by 180.4% during the 4th quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock valued at $754,000 after buying an additional 2,978 shares during the period. Empowered Funds LLC boosted its stake in shares of Zoetis by 6.2% in the 1st quarter. Empowered Funds LLC now owns 11,293 shares of the company’s stock worth $1,859,000 after buying an additional 657 shares during the last quarter. Intech Investment Management LLC grew its holdings in shares of Zoetis by 17.2% in the first quarter. Intech Investment Management LLC now owns 8,347 shares of the company’s stock worth $1,374,000 after acquiring an additional 1,224 shares during the period. Sivia Capital Partners LLC grew its holdings in shares of Zoetis by 73.8% in the second quarter. Sivia Capital Partners LLC now owns 3,348 shares of the company’s stock worth $522,000 after acquiring an additional 1,422 shares during the period. Finally, Glenview Trust co increased its position in Zoetis by 11.8% during the second quarter. Glenview Trust co now owns 4,780 shares of the company’s stock valued at $745,000 after acquiring an additional 506 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Trading Down 2.9%

Shares of NYSE:ZTS opened at $73.64 on Friday. The stock has a 50 day moving average of $76.30 and a 200 day moving average of $99.01. The company has a market cap of $30.43 billion, a PE ratio of 12.13, a price-to-earnings-growth ratio of 1.28 and a beta of 0.74. Zoetis Inc. has a 12-month low of $71.45 and a 12-month high of $160.48. The company has a current ratio of 3.08, a quick ratio of 1.84 and a debt-to-equity ratio of 2.87.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, August 6th. The company reported $1.87 EPS for the quarter, topping analysts’ consensus estimates of $1.85 by $0.02. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The company had revenue of $2.47 billion for the quarter, compared to analysts’ expectations of $2.50 billion. During the same quarter last year, the business earned $1.76 EPS. The firm’s revenue was down .2% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, equities research analysts expect that Zoetis Inc. will post 6.19 EPS for the current year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be given a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a dividend yield of 2.9%. The ex-dividend date is Monday, July 20th. Zoetis’s dividend payout ratio (DPR) is presently 34.93%.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the company. Piper Sandler lowered their target price on Zoetis from $90.00 to $80.00 and set a “neutral” rating on the stock in a report on Monday, August 10th. JPMorgan Chase & Co. cut their price target on Zoetis from $130.00 to $115.00 and set an “overweight” rating for the company in a research note on Friday, August 7th. Zacks Research lowered shares of Zoetis from a “hold” rating to a “strong sell” rating in a research report on Monday, August 10th. UBS Group lowered their price objective on shares of Zoetis from $85.00 to $80.00 and set a “neutral” rating on the stock in a research note on Friday, August 7th. Finally, Stifel Nicolaus dropped their price objective on shares of Zoetis from $95.00 to $85.00 and set a “hold” rating on the stock in a report on Friday, June 26th. Eight investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $109.62.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.